Caroline Germa - Mar 1, 2024 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Medical Officer
Signature
/s/ Mark Manfredi, as Attorney-in-Fact for Caroline Germa
Stock symbol
IKNA
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 04:05 PM
Previous filing
Mar 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +579K $0.00 579K Mar 1, 2024 Common Stock 579K $1.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the shares subject to this option shall vest and become exercisable on September 1, 2024, with the remainder vesting in forty-two (42) equal monthly installments thereafter.